 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that URGN's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

UroGen Pharma (URGN, $15.09) RSI Indicator left the oversold zone on September 27, 2023

For the last three days, A.I.dvisor has detected that URGN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

UroGen Pharma (URGN, $15.09) Aroon Indicator entered a Downtrend on September 27, 2023.

UroGen Pharma (URGN, $15.44) Aroon Indicator entered a Downtrend on September 26, 2023.

UroGen Pharma (URGN, $15.81) Aroon Indicator entered a Downtrend on September 25, 2023.

This price move could indicate a change in the trend, and may be a sell signal for investors...

UroGen Pharma (URGN, $16.15) price exceeded its 50-day Moving Average on September 12, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September: H.C. Wainwright 25th Annual Global Investment...

UroGen Pharma to Present at Upcoming Investor Conferences

This indicator may be signaling that URGN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

UroGen Pharma (URGN, $20.27) entered Downtrend as Momentum indicator drops below 0 level on Aug 22, 2023

Key Insights Significantly high institutional ownership implies UroGen Pharma's stock price is sensitive to their...

UroGen Pharma Ltd.'s (NASDAQ:URGN) institutional investors lost 13% last week but have benefitted from longer-term gains

UroGen Pharma (URGN, $18.43) entered Downtrend as Momentum indicator drops below 0 level on Aug 17, 2023

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Watchers	1,026
52-Wk Low	$7.08
52-Wk High	$24.13

Market Cap	$432.74M
Volume (M)	3,524.00
52-Wk High	$24.13
52-Wk Low	$7.08

URGN UroGen Pharma Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals